Diagnostic value of determination of galectin-3 - the new biomarker of the chronic heart failure

封面

如何引用文章

全文:

详细

The reviewsummarizes the results of clinical trials in which galectin-3 was assessed as biomarker of heart failure. In addition, most relevant information on galectin-3 received in in vitro and in vivo research is given with respect of heart failure.

作者简介

K. Gyamdzhyan

Department of Clinical Pharmacology and Internal Propaedeutic Medicine, Sechenov first medical university

аспирант каф. клинической фармакологии и пропедевтики внутренних болезней

M. Maksimov

Department of Clinical Pharmacology and Internal Propaedeutic Medicine, Sechenov first medical university

д-р мед. наук, проф. каф. клинической фармакологии и пропедевтики внутренних болезней

参考

  1. Агеев Ф.Т., Арутюнов Г.П. Хроническая сердечная недостаточность. М.: ГЭОТАР-Медиа, 2010.
  2. Ho J.M et al. Galectin-3, a marker of cardiac fibrosis, predicts incidence heart failure in the community. JACC 2012; 60 (14):1249-56.
  3. Максимов М.Л. Влияние кардиоселективного бета - блокатора небиволола на глобальную и локальную сократимость миокарда у больных ишемической болезнью сердца, осложненной хронической сердечной недостаточностью. Автореф. дис. ... канд. мед. наук. М., 2004.
  4. Агеев Ф.Т., Азизова А.Г. Галектин-3 - новый биохимический маркер сердечной недостаточности. Журн. Сердечная недостаточность. 2011; 12 (2).
  5. Драпкина О.М., Дуболазова Ю.В. Применение биологических маркеров в диагностике диастолической сердечной недостаточности. Журн. Сердечная недостаточность. 2011; 12 (6).
  6. Kramer F. Galectin-3: clinical utility and prognostic value in patients with heart failure. Reas Rep Clin Cardiology 2013; 4: 13-2.
  7. Kim H, Lee J et al. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 2007; 31 (7): 655-2.
  8. Ochieng J et al. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun 1998: 246 (3): 788-91.
  9. Karlsson A et al. Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology 2009; 19 (1): 16-20.
  10. Sharma U.C et al. Galectin-3 marks activated macrophages in failure - prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110 (19): 3121-8.
  11. Shroen B, Heymans S et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure - prone cardiac hypertrophy. Circ Res 2004; 95 (5): 515-22.
  12. Henderson N.C et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006; 103 (13): 5060-5.
  13. Liu Y.H et al. N-acetyl - seryl - aspartyl - lysyl - proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth - regulatory lectin. Am J Physiol Heart Circ Physiol 2009; 296 (2): H404-H412.
  14. Calvier L et al. Galectin-3 mediates aldosterone - induced vascular fibrosis. Atheroscler Thromb Vasc Biol 2013; 33 (1): 67-75.
  15. de Boer R.A et al. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010; 7 (1): 1-8.
  16. van Kimmenade R.R et al. Utility of aminoterminal pro - brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48 (6): 1217-24.
  17. Дуболазова Ю.В. Оценка клинического течения хронической сердечной недостаточности с сохраненной фракцией выброса. Автореф. дис. ... канд. мед. наук. М., 2012.
  18. Gullestad L et al. CORONA Study group. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J 2012; 33 (18): 2290-6.
  19. Kjekhus J et al. CORONA group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357 (22): 2248-61.
  20. Cohn J.N et al. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin - receptor blocker valsartan in chronic heart failure. N Eng J Med 2001; 345 (23): 1667-75.
  21. Anand I.S et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the ValHeFT. Eur J of Heart Failure Epub 2013, Jan 4.
  22. Milting H et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008; 27 (6): 589-96.
  23. Erkilet G et al. Plasma galectin-3 is increased in terminal heart failure patients and is elevated in patients surviving mechanical circulatory support. J Heart Lung Transplant 2010; 29 (2): S65.
  24. Lopez-Andrez N et al. Association of galectin-3 and fibrosis markers with long - term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction and dyssynchrony: insights from CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012; 14 (1).
  25. Lok D.J et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. Epub August 12, 2012
  26. Felker G.M et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012; 5 (1): 72-8.
  27. Lok D.J et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from DEAL-HF study. Clin Res Cardiol 2010; 99 (5): 323-28.
  28. Erkilet G et al. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. J Heart Lung Transplant 2013; 32 (2): 221-30.
  29. de Boer R.A et al. Predictive values of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43 (1): 60-8.
  30. Shah R.V et al. Galectin-3, cardiac structure and function and long - term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010; 12 (8): 826-32.
  31. de Boer R.A et al. The fibrosis marker galectin-3 and outcome in general population. J Intern Med 2012; 272 (1): 55-64.
  32. Biomarker Definitions Working Group. Biomarkers and surrogate end - points: preffered definitions and conceptual framework. Clin Pharmacol Ther 2001; 69 (3): 89-95.

版权所有 © Eco-Vector, 2014

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。

##common.cookie##